Pfizer faces disappointment with anticancers after more Phase III failures
12 March 2010
Malini Guha
Pfizer is facing more disappointment with the development of some of its most advanced anticancers after Sutent (sunitinib) failed two more Phase III trials in advanced breast cancer - which could spell the end for the drug in the disease - and figitumumab (CP-751,871), one of the most advanced...
Please Login to read the full article.
12 March 2010
Malini Guha
Please Login to read the full article.
RELATED CONTENT
NEWS
- Immatics receives Pfizer's 'support' for pivotal IMA901 trial in RCC
- Astellas mulls darexaban alliances as pipeline moves forward
- GSK expands tiered pricing approach in India with Votrient and Revolade launches
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
